n/estimation | % | |
---|---|---|
Age (years) | ||
Mean ± standard deviation | 58.4 ± 10.2 | |
Median (range) | 59 (29–78) | |
ECOG performance status on chemotherapy day 1 | ||
0 | 42 | 39 |
1 | 57 | 53 |
2 | 8 | 7 |
HER2 overexpression | ||
2+/FISH + | 8 | 7 |
3+ | 97 | 90 |
FISH +/no immunohistochemistry or other | 3 | 3 |
Tumor grade (n = 102) | ||
G1 | 2 | 2 |
G2 | 47 | 46 |
G3 | 53 | 52 |
Metastatic sites at onset of study treatment (n) | ||
Mean ± standard deviation | 1.8 ± 0.9 | |
Median, range | 2 (1–5) | |
Organ site involvement | ||
Local/skin | 14 | 13 |
Lymph nodes, non-regional | 20 | 19 |
Bone | 41 | 38 |
Liver | 48 | 44 |
Lung | 49 | 45 |
Pleural effusion | 13 | 12 |
Genitourinary | 1 | 1 |
Other | 9 | 8 |
Previous treatment | ||
Neoadjuvant chemotherapy | 11 | 10 |
Adjuvant chemotherapy | 74 | 69 |
Adjuvant endocrine therapy | 45 | 42 |
Palliative chemotherapy | 40 | 37 |
Palliative endocrine therapy | 34 | 31 |